Key Takeaways
- • Three major hedge funds accumulated CVS shares in Q3 2024: Glenview Capital bought 2.8 million shares (31% increase to 0.95% stake), Sachem Head added over 1 million shares (44% increase to 0.28% stake), and Third Point established a new 1.6 million-share position (0.13% stake), all before the October CEO transition.
- • CVS shares declined 32% year-to-date through the filing period, driven by deteriorating financial forecasts and operational challenges that attracted activist investor attention and precipitated leadership change from Karen Lynch to David Joyner.
- • Sachem Head elevated CVS to its second-largest holding, signaling conviction in turnaround potential, while Glenview positioned itself as a "constructivist shareholder" engaging directly with management on strategic changes without calling for a company breakup.
- • Activist pressure preceded formal CEO replacement: Glenview's Larry Robbins met with CVS executives during the summer to push for changes, and analysts speculated additional investor demands could follow, though neither Sachem Head nor Third Point had made public demands as of the filing date.
- • Strategic positioning ahead of operational reset: The synchronized accumulation by three sophisticated investors reflects confidence in CVS's recovery trajectory under new leadership and potential for operational or strategic restructuring.
Summary
Three prominent hedge funds signaled confidence in CVS Health's turnaround prospects by substantially increasing positions during the third quarter of 2024, according to regulatory 13-F filings reviewed by Reuters. The coordinated accumulation—involving Glenview Capital Management, Sachem Head Capital Management, and Third Point—preceded the healthcare giant's October announcement of David Joyner as the new chief executive officer, replacing Karen Lynch amid mounting operational and financial pressures.
Glenview Capital, an established CVS investor, expanded its position most aggressively with a 2.8 million share purchase representing a 31% increase, bringing its ownership stake to 0.95% of the company by quarter-end. Sachem Head, under the leadership of former Pershing Square partner Scott Ferguson, added over 1 million shares during the same period, raising its stake by 44% and elevating CVS to its second-largest holding at 0.28% ownership. Third Point, led by billionaire investor Daniel Loeb, initiated an entirely new position by purchasing 1.6 million shares, acquiring a 0.13% stake. All three transactions occurred as CVS shares had declined 32% since the start of the year, weighed down by increasingly pessimistic financial guidance and operational headwinds.
The accumulation reflects investor conviction that meaningful changes lie ahead at the struggling healthcare conglomerate. Glenview's Larry Robbins, who characterizes himself as a constructivist shareholder, engaged directly with CVS management during the summer months to advocate for operational reforms, though he explicitly did not push for a company breakup. Market observers had anticipated that additional investors might follow with more vocal demands for transformation, including leadership changes. At the time of the Q3 filings, however, neither Sachem Head nor Third Point had made public activist demands, suggesting a coordinated strategy focused on supporting management's turnaround initiatives rather than adversarial intervention.
The timing of these purchases—made before the CEO succession announcement—indicates these investors identified fundamental value in CVS ahead of the leadership transition, positioning themselves to benefit from anticipated operational improvements and strategic repositioning under new executive leadership.
Glenview Capital, an established CVS investor, expanded its position most aggressively with a 2.8 million share purchase representing a 31% increase, bringing its ownership stake to 0.95% of the company by quarter-end. Sachem Head, under the leadership of former Pershing Square partner Scott Ferguson, added over 1 million shares during the same period, raising its stake by 44% and elevating CVS to its second-largest holding at 0.28% ownership. Third Point, led by billionaire investor Daniel Loeb, initiated an entirely new position by purchasing 1.6 million shares, acquiring a 0.13% stake. All three transactions occurred as CVS shares had declined 32% since the start of the year, weighed down by increasingly pessimistic financial guidance and operational headwinds.
The accumulation reflects investor conviction that meaningful changes lie ahead at the struggling healthcare conglomerate. Glenview's Larry Robbins, who characterizes himself as a constructivist shareholder, engaged directly with CVS management during the summer months to advocate for operational reforms, though he explicitly did not push for a company breakup. Market observers had anticipated that additional investors might follow with more vocal demands for transformation, including leadership changes. At the time of the Q3 filings, however, neither Sachem Head nor Third Point had made public activist demands, suggesting a coordinated strategy focused on supporting management's turnaround initiatives rather than adversarial intervention.
The timing of these purchases—made before the CEO succession announcement—indicates these investors identified fundamental value in CVS ahead of the leadership transition, positioning themselves to benefit from anticipated operational improvements and strategic repositioning under new executive leadership.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.